ArticleJournal of translational medicine2005
Immunologic aspect of ovarian cancer and p53 as tumor antigen.
Article in Journal of translational medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy.Apoptosis : an international journal on programmed cell death · 2026Review
- Protein ubiquitination in ovarian cancer immunotherapy: The progress and therapeutic strategy.Genes & diseases · 2024Review
- DNA-delivered monoclonal antibodies targeting the p53 R175H mutant epitope inhibit tumor development in mice.Genes & diseases · 2024Article
- A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development.Frontiers in cell and developmental biology · 2021Review
- Immunotherapy Advances for Epithelial Ovarian Cancer.Cancers · 2020Review
- Development of Therapeutic Vaccines for Ovarian Cancer.Vaccines · 2020Review
- P53: A Guardian of Immunity Becomes Its Saboteur through Mutation.International journal of molecular sciences · 2020Review
- Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer.Medicine · 2017Article
- Review
- Phase I dendritic cell p53 peptide vaccine for head and neck cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy.BioMed research international · 2014Article
- Pharmacological activation of p53 in cancer cells.Current pharmaceutical design · 2011Review
- Translating p53 into the clinic.Nature reviews. Clinical oncology · 2011Review
- Article
- Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.Journal of biomedicine & biotechnology · 2011Review
- Potential target antigens for a universal vaccine in epithelial ovarian cancer.Clinical & developmental immunology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer represents the fifth leading cause of death from all cancers for women. During the last decades overall survival has improved due to the use of new chemotherapy schedules. Still, the majority of patients die of this disease. Research reveals that ovarian cancer patients exhibit significant immune responses against their tumor. In this review the knowledge obtained thus far on the interaction of ovarian cancer tumor cells and the immune system is discussed. Furthermore the role of p53 as tumor antigen and its potential role as target antigen in ovarian cancer is summarized. Based on the increased knowledge on the role of the immune system in ovarian cancer major improvements are to be expected of immunotherapy based treatment of this disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.